Cancer Genetics (CGIX) PT Set at $6.00 by Maxim Group
Cancer Genetics (NASDAQ:CGIX) received a $6.00 price target from stock analysts at Maxim Group in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the medical research company’s stock. Maxim Group’s price objective suggests a potential upside of 207.69% from the stock’s current price.
Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Cancer Genetics in a research note on Thursday, September 21st. Zacks Investment Research raised shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Finally, ValuEngine cut shares of Cancer Genetics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.56.
Cancer Genetics (NASDAQ CGIX) opened at $1.95 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. Cancer Genetics has a one year low of $1.30 and a one year high of $5.30.
In related news, Director John Pappajohn bought 150,000 shares of the firm’s stock in a transaction on Friday, December 8th. The shares were purchased at an average price of $1.86 per share, with a total value of $279,000.00. Following the completion of the purchase, the director now owns 2,781,204 shares in the company, valued at approximately $5,173,039.44. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 21.30% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its holdings in shares of Cancer Genetics by 44.8% during the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock worth $1,843,000 after purchasing an additional 139,200 shares during the period. Thompson Davis & CO. Inc. lifted its holdings in shares of Cancer Genetics by 5,465.0% during the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock worth $440,000 after purchasing an additional 109,300 shares during the period. Northern Trust Corp lifted its holdings in shares of Cancer Genetics by 61.0% during the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after purchasing an additional 12,168 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Cancer Genetics by 61.9% during the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after purchasing an additional 197,619 shares during the period. Finally, Granahan Investment Management Inc. MA lifted its holdings in shares of Cancer Genetics by 26.3% during the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after purchasing an additional 49,371 shares during the period. 12.71% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/cancer-genetics-cgix-pt-set-at-6-00-by-maxim-group/1764603.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.